Qmed+

Cover Block

PUBLIC

Attribute	Value
Name	Qmed+
Tagline	World’s only directory of pre-qualified suppliers to medical device and diagnostics industry. [Crunchbase]
Business Model	Marketplace
Industry	Healthtech
Technology	Software (Non-AI)

Note: Headquarters location, founding year, stage, geography, growth profile, founding team, and funding details are not publicly available.

Links

PUBLIC

• Website: https://qmed.com/
• LinkedIn: https://www.linkedin.com/showcase/qmed-news

Executive Summary

PUBLIC

Qmed+ operates a specialized supplier directory for the medical device and diagnostics industry, a niche that merits investor attention due to the critical, high-stakes nature of supplier qualification in a heavily regulated sector [Crunchbase]. The platform's stated purpose is to accelerate the discovery of partners who already hold certifications like ISO 13485 and FDA registration, aiming to reduce the time and compliance risk for device manufacturers sourcing components and services [Perplexity Sonar Pro, Unknown]. Its core differentiation is the claim to be the world's only directory focused exclusively on pre-qualified suppliers, filtering for specific regulatory and experience benchmarks that are non-negotiable in medtech [Crunchbase].

The founding story and team background are not publicly disclosed, which presents a significant gap in the standard startup narrative. Similarly, the company's funding history, business model, and capital structure remain outside of public view. This absence of foundational data makes it difficult to assess operational maturity or financial runway. Over the next 12-18 months, the key indicators to watch will be any emergence of traction metrics, customer case studies, or partnership announcements that could validate the directory's adoption and commercial model.

Data Accuracy: YELLOW -- Core product claims are sourced from the company's own materials and a third-party summary; foundational company data (team, funding) is absent.

Taxonomy Snapshot

Axis	Value
Business Model	Marketplace
Industry / Vertical	Healthtech
Technology Type	Software (Non-AI)

Company Overview

PUBLIC

Qmed+ presents a straightforward, if opaque, corporate profile. The service is a specialized online directory for the medical device and diagnostics industry, described on its own website as "the world’s only directory of pre-qualified suppliers and service providers" to that sector [qmed.com]. Its core function is to help medical device and in vitro diagnostic companies find suppliers who meet specific regulatory and quality standards, such as ISO 13485 certification and FDA registration [Perplexity Sonar Pro].

Public records do not reveal a founding date, founding team, or headquarters location for the Qmed+ directory entity. The historical trail is complicated by brand confusion. The Qmed.com domain and associated directory were historically part of Canon Communications, a B2B media company serving the advanced manufacturing and medical device sectors. Canon Communications was acquired by UBM in 2010 for $287 million, and UBM's assets, including the Canon portfolio, were later folded into Informa PLC [InPublishing]. A 2013 press release refers to "UBM Canon and Qmed, the Global MedTech Authority" publishing a joint industry infographic [PR Newswire]. As of 2025, the directory remains active, publishing supplier news and maintaining listings [qmed.com].

This lineage suggests Qmed+ is likely a product line or digital asset within a larger corporate division, rather than a standalone, venture-backed startup. No funding rounds, leadership team, or significant corporate milestones specific to the directory are disclosed in available public sources. The primary milestone is the sustained operation of the directory itself, which continues to list suppliers and publish industry content.

Data Accuracy: YELLOW -- Company description confirmed by primary website; corporate history inferred from dated press releases and acquisition news. Key entity details (founding, team, HQ) are not publicly available.

Product and Technology

MIXED The core offering is a specialized online directory for sourcing certified suppliers in the medical device and diagnostics sector. The product's primary function is to accelerate supplier discovery by allowing medical device and in vitro diagnostics firms to search by keyword or category for vendors that meet specific regulatory and quality thresholds [Perplexity Sonar Pro]. The claimed differentiator is a pre-qualification process, with the site stating it is the world's only directory of completely pre-qualified suppliers to these industries [qmed.com, Crunchbase].

Supplier profiles are designed to be comprehensive, consolidating information that would otherwise require manual verification. According to the company's description, each profile includes an overview, contact details, qualifications, product listings, and methods for initiating a connection [Perplexity Sonar Pro]. The pre-qualification criteria reportedly include certifications such as ISO 13485, compliance with Current Good Manufacturing Practice (CGMP), FDA registration, and demonstrated experience working within the medtech industry [Perplexity Sonar Pro]. The website also hosts a "Supplier News" section with updates posted for 2025, indicating an active, if basic, content component [qmed.com].

No details about the underlying technology stack, development roadmap, or API availability are disclosed on the public site. The product appears to be a software-as-a-service (SaaS) marketplace with a focus on curated data rather than transactional features. The absence of any mention of artificial intelligence or machine learning in the source material suggests the platform's value is derived from its manually vetted dataset and search functionality, not from predictive algorithms.

Data Accuracy: YELLOW -- Product claims are sourced from the company's own website and a secondary aggregator; technical implementation and active user metrics are not publicly verified.

Market Research and Opportunity

PUBLIC The core appeal of Qmed+ lies in its attempt to bring order to a notoriously fragmented and high-stakes procurement process, where the cost of a supplier error is measured in regulatory delays or patient safety.

Quantifying the total addressable market for a specialized supplier directory is challenging due to a lack of direct, cited sizing for this niche. However, the broader medical device manufacturing market provides a relevant analog. According to a 2023 report from Grand View Research, the global medical device contract manufacturing market was valued at approximately $81.5 billion and is projected to grow at a compound annual growth rate of 10.5% through 2030 [Grand View Research, 2023]. This figure represents the total value of outsourced manufacturing, a significant portion of which flows through the supplier ecosystem Qmed+ aims to organize. The serviceable obtainable market is a narrower slice, focused on the discovery and qualification phase for components, materials, and specialized services within that larger manufacturing spend.

Several demand drivers underpin this market. Regulatory complexity is a primary accelerator; medical device companies must ensure their entire supply chain complies with standards like ISO 13485 and FDA Quality System Regulations. The manual process of verifying these certifications for each potential supplier is a significant time and compliance burden. A second driver is the industry's push for innovation and speed-to-market. As device makers develop more complex products, they require specialized suppliers (e.g., for micro-molding, biocompatible coatings, or AI-enabled software components) that are difficult to find through traditional networks. Supply chain resilience, heightened by recent global disruptions, is a third tailwind, pushing OEMs to diversify their supplier base with pre-vetted alternatives.

Key adjacent markets include general industrial B2B directories (like Thomasnet.com) and enterprise supplier relationship management (SRM) software platforms. These represent substitute solutions, though they lack the medtech-specific pre-qualification focus Qmed+ claims. The regulatory environment itself is a double-edged force: it creates the pain point Qmed+ addresses but also imposes a high burden of continuous verification on the directory operator to maintain its value proposition. Any lapse in keeping supplier credentials current would rapidly erode user trust.

Data Accuracy: YELLOW -- Market sizing is inferred from analogous, broader industry reports. Specific TAM/SAM for the supplier directory niche is not publicly available from independent sources.

Competitive Landscape

MIXED Qmed+ enters a market where procurement is fragmented across generalist directories, specialized consultancies, and direct sales relationships, positioning itself as a dedicated, pre-vetted channel for a niche but critical component of the medtech supply chain.

The competitive map for supplier discovery in medical devices is not dominated by a single platform but is instead split across several distinct approaches. Incumbent directories like Thomasnet.com and Alibaba.com offer broad industrial sourcing but lack the specific certification vetting and industry context required for regulated medical device components. Specialized consultancies, such as the unrelated QMED Consulting based in Copenhagen, compete indirectly by offering full-service supplier qualification as part of a broader regulatory and quality advisory package [Perplexity Sonar Pro, Unknown]. The most direct substitutes are the internal procurement teams and quality assurance departments within large medical device OEMs, which build and maintain proprietary supplier lists through costly audit processes. This creates a competitive environment defined by a trade-off between breadth and specialized trust.

Where Qmed+ claims a defensible edge is in its singular focus on pre-qualification for medical device and IVD suppliers. Its public value proposition hinges on being the "world’s only directory" where every listed supplier meets a baseline of certifications like ISO 13485, CGMP, and FDA registration [Crunchbase, Unknown]. This curated-data edge is theoretically durable if the company can maintain rigorous, up-to-date verification processes that generalist platforms cannot justify for a narrow vertical. However, this edge is also perishable; it depends entirely on the accuracy and comprehensiveness of the underlying data. A failure to scale verification or to keep profiles current would quickly erode the platform's core value, as users would revert to trusted consultancies or their own audits.

The platform is most exposed to competition from adjacent software categories and from the consultancies it aims to partially displace. A company like Greenlight Guru or Qualio, which provides quality management system (QMS) software for medtech, could logically extend its platform to include a vetted supplier network, leveraging its existing customer base and deeper integration into the quality workflow. Furthermore, the specialized consultancies hold a significant advantage in high-stakes, high-value supplier selection for critical components, where their advisory relationship and assumed liability offer reassurance that a directory profile cannot. Qmed+ does not currently own a direct sales or integration channel into the enterprise resource planning (ERP) or product lifecycle management (PLM) systems where procurement decisions are ultimately executed, leaving it vulnerable to being sidelined as merely an initial research tool.

The most plausible 18-month scenario is one of continued niche occupancy without dramatic market share shifts. The winner in this period will be the entity that successfully bridges the gap between directory listing and transaction, perhaps by integrating supplier quality data directly into a QMS platform or by forging a formal partnership with a major industry association. The loser will be any standalone directory that fails to demonstrate measurable time or cost savings for procurement teams, as they will be viewed as a marginally useful supplement rather than a necessary utility. For Qmed+, the critical test is whether it can transition from being a static directory to becoming a dynamic part of the medtech sourcing workflow.

Data Accuracy: YELLOW -- Competitive analysis is based on the company's stated positioning and identified adjacent players; direct head-to-head comparison with named, funded startups in the exact same category is not possible from available public sources.

Opportunity

PUBLIC

If Qmed+ can establish itself as the definitive, trusted source for supplier discovery in the global medical device industry, it would capture a critical and recurring workflow in a multi-trillion-dollar supply chain.

The headline opportunity is for Qmed+ to become the category-defining, de facto standard for supplier qualification and sourcing in medical technology. The company’s cited positioning as the “world’s only directory of completely pre-qualified suppliers” [Crunchbase] directly targets a persistent, high-friction process. For medical device and diagnostics companies, the cost of a supplier failure is not just financial but regulatory, potentially delaying product launches and inviting FDA scrutiny. A platform that reliably aggregates and verifies critical compliance data,ISO 13485, FDA registration, CGMP status,addresses a genuine pain point around risk mitigation and speed [Perplexity Sonar Pro, Unknown]. The outcome is reachable because the value proposition is rooted in compliance, a non-negotiable cost center for the industry, rather than discretionary spending on marketing or lead generation.

Growth would likely follow one of several concrete paths, each hinging on a specific catalyst.

Scenario	What happens	Catalyst	Why it's plausible
Platform-as-a-Service for OEMs	Large device manufacturers embed Qmed+’s directory and verification tools directly into their internal procurement and quality management systems.	A strategic partnership with a top-10 medical device OEM, announced as a preferred sourcing tool.	The directory’s structure and focus on pre-qualification suggest a product built for enterprise integration, not just casual browsing. A historical precedent exists: the platform was previously part of UBM Canon, a major trade show and media organizer for the industry [PR Newswire, Unknown], indicating legacy relationships with large manufacturers.
Data Licensing & Risk Analytics	The proprietary dataset of supplier qualifications becomes a feed for third-party risk management platforms, insurance underwriters, and audit firms.	Launch of an API or data feed product, with an early customer in the medtech insurance sector.	The core asset is structured data on supplier compliance. As the database grows, its value for predictive risk scoring and market intelligence increases independently of the directory’s user interface.

Compounding for Qmed+ would manifest as a classic two-sided network effect reinforced by a data moat. Each new supplier paying for a comprehensive profile enriches the directory for buyers. Each new buyer conducting serious searches increases the incentive for suppliers to maintain and update their profiles with current certifications. This cycle generates a proprietary dataset of qualification statuses, audit dates, and specializations that becomes increasingly difficult and expensive for a new entrant to replicate. Evidence that this flywheel is in motion is limited, but the publication of “Supplier News 2025” on its site [qmed.com, Unknown] indicates an active effort to engage the supplier side with fresh content, a common tactic for boosting platform liquidity.

The size of the win can be framed by looking at comparable businesses in adjacent verticals. Companies like Thomasnet (industrial supplier sourcing) and PharmaCircle (pharmaceutical industry intelligence) have established significant enterprise value by owning curated B2B supply chain data. While a direct public comparable is not available, the model suggests that owning a critical, compliance-driven search layer in a specialized, high-stakes industry can support a valuation based on high-margin SaaS or data licensing revenue. If the “Platform-as-a-Service” scenario plays out and Qmed+ achieves penetration as a mandated tool within several major OEMs, the company could plausibly build a business with an enterprise value in the high tens to low hundreds of millions of dollars, based on capturing a small percentage of the industry’s enormous supplier qualification and procurement budget. This is a scenario-specific outcome, not a forecast.

Data Accuracy: YELLOW -- Core product claims are sourced from the company's own website and a secondary database, but growth scenarios and compounding mechanics are largely inferred from the business model, not from public traction metrics.

Sources

PUBLIC

1. [Crunchbase] Qmed - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/qmed

2. [Perplexity Sonar Pro] Qmed+ (qmed.com) Brief | https://www.perplexity.ai/

3. [qmed.com] Discover Qualified Medical Suppliers You Can Trust | QMED+ | https://qmed.com/

4. [InPublishing] InPublishing: UBM acquires Canon Communications for $287m | https://www.inpublishing.co.uk/articles/ubm-acquires-canon-communications-for-287m-12695

5. [PR Newswire] UBM Canon and Qmed, the Global MedTech Authority, Publishes New Infographic Examining OEMs and Their Suppliers | https://www.prnewswire.com/news-releases/ubm-canon-and-qmed-the-global-medtech-authority-publishes-new-infographic-examining-oems-and-their-suppliers-215651211.html

6. [Grand View Research, 2023] Medical Device Contract Manufacturing Market Size Report, 2023-2030 | https://www.grandviewresearch.com/industry-analysis/medical-device-contract-manufacturing-market